Drug intelligence / Profile preview

nubytide

Development stage: Unknown
Lead developer: Cenna Biosciences
Modality: Peptides, Small Molecules
Administration: Subcutaneous

Overview

Nubytide is a first-in-class, disease-modifying peptide drug developed by Cenna Biosciences for the prevention and treatment of Alzheimer's disease. It acts as an amyloid beta-protein inhibitor, reducing the production of amyloid-beta (Aß), which is implicated in the pathogenesis of Alzheimer's disease. Preclinical data suggest that Nubytide not only lowers Aß levels but also reduces markers of inflammation and tau pathology, offering a differentiated approach compared to current monoclonal antibody therapies. The drug is designed to be affordable, easy to administer (by subcutaneous injection), and potentially safer than existing options[1][2][8].

Brand names: Nubytide
Other names: Nubytide

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on nubytide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nubytide.

Explore the full profile